Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion
Portfolio Pulse from
Collegium Pharmaceutical is experiencing strong growth driven by its pain management portfolio and expansion into the ADHD market through the acquisition of Jornay PM. The company reported a 17% YoY revenue growth and improved EBIT margins in Q3 2024.
November 26, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Collegium Pharmaceutical's strong Q3 2024 results and strategic expansion into the ADHD market through the acquisition of Jornay PM highlight its growth potential. The company's focus on pain management and abuse-deterrent therapies continues to drive significant revenue.
Collegium Pharmaceutical's Q3 2024 results show a 17% YoY revenue growth and improved EBIT margins, indicating strong operational performance. The acquisition of Jornay PM allows COLL to enter the growing ADHD market, which is expected to reach $30.6 billion by 2032. This strategic move, combined with its leadership in pain management, positions COLL for continued growth.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100